You can buy sermorelin from a compounding pharmacy on a prescription, or from a research-chemical supplier without one. Those are the two answers to where to buy sermorelin, and no retail pharmacy is among them. The branded drug stopped being sold, and everything about sourcing it follows from that.
Sermorelin is GHRH(1-29), the first growth-hormone secretagogue, and it was an approved drug called Geref. It was pulled for business reasons, not safety, which is why a compounding pharmacy can still prepare it. The peptide runs 29 residues, is cheap to make and rarely faked, so check it for breakdown rather than identity.
Sermorelin sits in an unusual position. It's a molecule with genuine 1990s clinical data behind it and no branded product. Understanding why changes how you buy it.
Where can you buy sermorelin?
You can buy sermorelin two ways, and they aren't equivalent.
- A compounding pharmacy, on prescription. Sermorelin is one of the few peptides genuinely available this way, because it has an established active ingredient and a clinical history. A prescriber has to write for it. The 503A route covers how that works and where it's contested.
- A research-chemical supplier, no prescription. Lyophilized powder under Research Use Only labeling. No prescriber, no pharmacy, and no regulator checking the batch. Verification is entirely on you and the certificate of analysis.
- A retail pharmacy. Closed. Geref is gone, so there's no finished product to dispense.
Which vendors should be on your sermorelin shortlist?
Take the research-supply route rather than the pharmacy one and the supplier is the entire quality system, so here is the shortlist. Of the 16 storefronts we checked on 13 August 2026, these six published the most: a third-party certificate that opens, and a lab named on it. The table scores the vendor rather than the catalog, so confirm sermorelin itself is stocked before ordering. Pricing across this set is benchmarked on BPC-157, the one compound all six carry; no sermorelin price was verified across these vendors, so there is no price column rather than an estimated one.
| Vendor | COA | Lab named | Ships free at |
|---|---|---|---|
| Peptriva Premium brand | Third-party, published | Freedom Diagnostics — on the product page | $200 |
| Sports Technology Labs | Third-party, published | MZ Biolabs and Colmaric — on the site and the document | $149 |
| Swiss Chems | Third-party, published | Janoshik — on the site | $100 |
| Core Peptides | Third-party, published (A2LA #6377.01.01) | Vanguard Laboratory — document only | $200 |
| PS Peptides | Third-party, published | North American Diagnostics — document only | $200 |
| BioTech Peptides | Third-party, published | MZ Biolabs — document only | $200 |
Three vendors from the same survey are absent on purpose. Red Rock Peptides advertises “Verified With COAs” and publishes no certificate at all. Limitless Biotech gates every price behind an account, so nothing it offers can be compared against anything. Behemoth Labz does publish, but its newest genuine certificate is dated August 2024. The full ranking, with the price column, is in our comparison of peptide companies. Disclosure: this site earns a commission on purchases made through its links, Peptriva included — which is why every column above is a document you can open or a figure you can load for yourself.
No verified CAS number or reference mass for sermorelin sits in the dataset behind this table, so require them on the certificate instead: a mass-spec identity line for GHRH(1-29), a purity figure that names truncated sequences rather than reporting one percentage, and a lot number matching your vial.
Why is there no branded sermorelin?
Sermorelin lost its brand, Geref, for commercial reasons: a small market, competition from recombinant growth hormone, and the cost of keeping a license alive. It was not a safety withdrawal.
That distinction is the whole story. A compound pulled for safety and a compound pulled for margin are very different propositions, and sermorelin is the second. It's also why the compounding route above is open at all.
How do you check a sermorelin vial?
Sermorelin is short and cheap, so nobody bothers faking it. Your risk is a degraded vial rather than a substituted one. That flips the usual checklist: cold chain and solution stability matter more here than identity.
| Check | Why it matters here |
|---|---|
| Identity by mass spec | Standard, but low-risk: at 29 residues sermorelin is cheap enough that substitution rarely pays |
| Purity and truncated sequences | The real synthesis risk — deletion peptides missing residues near the N-terminus |
| Lyophilized, not pre-mixed | Sermorelin's short half-life makes solution stability the binding constraint |
| Cold-chain shipping | The most common source of a dud vial in this compound |
| Cost per mg, normalized | Vial sizes vary widely; the sticker rarely reflects the unit cost |
- Ask the compounding pharmacy who compounds it and whether the sermorelin comes from an FDA-registered bulk supplier.
- Ask for the lot's certificate of analysis and check that it names truncated sequences, not just a purity percentage.
- Ask how it ships. Cold chain is the single most common reason a sermorelin vial arrives dead.
- Ask what the vial holds in milligrams so you can normalize the price. Vial sizes vary enough that the sticker tells you little.
“
Endocrine and metabolic effects of long-term administration of growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
— Khorram et al., Journal of Clinical Endocrinology & Metabolism, 1997. Still the core clinical reference we have.
Sermorelin's honest before-and-after is a blood test. The 1990s trials measured IGF-1 restored toward the young-adult range within about two weeks.
They didn't measure body composition in healthy trained adults, and no modern trial has either. So we'd treat any sermorelin transformation photo as outside the evidence. Our piece on what the trials actually showed lays out the numbers.
Growth-hormone axis compounds
Growth-hormone-axis research compounds, including tesamorelin, CJC-1295 and ipamorelin, each shipped with a batch-matched third-party certificate of analysis.
What do people buy instead of sermorelin?
Most buyers who start on sermorelin end up on tesamorelin or CJC-1295. Tesamorelin is the stabilized GHRH analog and the only compound in this class with a current FDA approval. CJC-1295 is the longer-acting one.
“
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
— Walker, Clinical Interventions in Aging, 2006. The title is a question, and it stayed one.
Our head-to-head covers half-life, evidence depth and cost. The class overview puts all three in context.
Frequently asked questions
Is sermorelin still available?
Yes, through compounding pharmacies on prescription and through the research-chemical market. What no longer exists is the branded product, Geref, which was discontinued commercially rather than withdrawn for safety.
Why was sermorelin discontinued?
Commercial reasons — a small market, competition from recombinant growth hormone, and the cost of maintaining a license. It was not a safety withdrawal, which is why compounding pharmacies can still prepare it.
Is sermorelin better than CJC-1295?
Different, not better. Sermorelin is the native GHRH fragment with a very short half-life; CJC-1295 is engineered to last longer. The short half-life produces a more pulse-like profile, which is the argument for it.
What should a sermorelin COA show?
Mass-spec identity confirming the 29-residue sequence, HPLC purity, and ideally a note on truncated sequences — deletion peptides are the characteristic synthesis impurity at this length.
Growth-hormone axis compounds
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- Sermorelin is GHRH(1-29). It was the first growth-hormone secretagogue, and it was sold as an approved drug called Geref.
- Geref went for business reasons. The withdrawal was commercial rather than a safety action, which changes how you read its absence.
- Two routes remain. A compounding pharmacy is one, the research-chemical market is the other, and they are not the same thing.
- Check for breakdown, not identity. The peptide is short and cheap to make, so degradation is likelier than a deliberate fake.
- Many buyers end up elsewhere. Sermorelin is the original growth-hormone secretagogue, not the default choice on this market today.
What we’re watching
The sermorelin question we can't answer yet is whether anyone runs a modern trial. The clinical record is 1990s endocrine work in age-advanced adults, and nothing since has tested it in the population that actually buys it.
The other thing we're watching is the 503A compounding list. Sermorelin's place on it is what keeps the prescription route open, and that list has been contested since 2023.
References
- Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308. https://doi.org/10.2147/ciia.2006.1.4.307
- Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle²⁷]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2013). Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
- International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html